FDA Begins Publishing Raw Adverse Event Data From AERS
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's website includes quarterly data from its Adverse Events Reporting System. FDA's goal is to publish the AERS data within two weeks after the quarter's end.
You may also be interested in...
U.K. Adverse Events System Will Allow Patients To Submit Reports, Review Data
The Medicines & Healthcare Products Regulatory Agency will have a final system for direct patient reporting of adverse events by 2006, the agency says. MHRA seems to acknowledge the careful balance required to post adverse event data without deterring appropriate drug use.
MedDRA Electronic Adverse Event Reporting Produces Rise In Case Reports
The number of electronic reports submitted by the 13 companies using MedDRA has roughly doubled since May, CDER Senior Program Manager Andrea Feight says. FDA is working with other regulatory agencies to expand MedDRA terminology.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.